Stoke Therapeutics Reports Third Quarter Financial Results a

– STK-001: Q1 2024 readout expected to include end of Phase 1/2a study results and longer-term data on the effects of repeat dosing on seizure frequency, cognition, and behavior from the ongoing...

Related Keywords

Denmark , Italy , Bedford , Massachusetts , United States , United Kingdom , Cambridge , Cambridgeshire , American , Edwardm Kaye , , International Epilepsy Congress , Company Annual Report On Form , Augmentation Of Nuclear Gene Output Is Stoke , Exchange Commission , American Epilepsy Society , Stoke Therapeutics Inc , Acadia Pharmaceuticals , Nasdaq , Augmentation Of Nuclear Gene Output , Stoke Therapeutics , Chief Executive Officer , Dominant Optic Atrophy , Year To Date Financial , Collaboration Agreement , Autosomal Dominant Optic Atrophy , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act , Annual Report , Months Ended September , Markets ,